Published in Expert Opin Biol Ther on December 25, 2012
γδ T cells for cancer immunotherapy: A systematic review of clinical trials. Oncoimmunology (2014) 1.23
Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J Natl Compr Canc Netw (2013) 0.77
Update on the challenges and recent advances in cancer immunotherapy. Immunotargets Ther (2013) 0.75
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Androgen deprivation therapy for prostate cancer. JAMA (2005) 6.07
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res (2010) 2.45
Cancer vaccines: moving beyond current paradigms. Clin Cancer Res (2007) 2.40
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res (2006) 2.20
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci (2007) 1.89
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.87
Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol (2007) 1.84
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res (2011) 1.82
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res (2008) 1.81
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 1.72
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs (2009) 1.71
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res (2008) 1.60
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol (2005) 1.59
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res (2008) 1.56
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int (2013) 1.47
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int (2008) 1.41
Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) (2008) 1.38
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int (2009) 1.37
Costimulatory molecules as adjuvants for immunotherapy. Front Biosci (2006) 1.37
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther (2006) 1.33
A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int (2005) 1.33
An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer (2010) 1.32
A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin Cancer Res (2010) 1.30
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood (2012) 1.30
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest (2009) 1.23
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunother (2010) 1.17
Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res (2013) 1.16
Paradigm shifts in cancer vaccine therapy. Exp Biol Med (Maywood) (2008) 1.13
Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine (2007) 1.13
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother (2014) 1.13
Prostate cancer immunotherapy. Clin Cancer Res (2011) 1.11
Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol (2009) 1.11
Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol (2012) 1.09
Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol (2007) 1.07
Combining radiation and immunotherapy for synergistic antitumor therapy. Curr Opin Mol Ther (2009) 1.03
A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). Clin Breast Cancer (2006) 1.02
Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. J Immunol (2013) 1.01
Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. Expert Opin Biol Ther (2010) 0.99
The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. J Nucl Med (2012) 0.98
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother (2013) 0.98
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol Immunother (2011) 0.97
PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin Biol Ther (2007) 0.97
Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules. Clin Cancer Res (2005) 0.96
Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. Cancer Immunol Immunother (2013) 0.95
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int (2007) 0.95
From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Rev Vaccines (2011) 0.94
Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J Clin Oncol (2014) 0.94
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol (2009) 0.93
Serum antibodies to blood group A predict survival on PROSTVAC-VF. Clin Cancer Res (2013) 0.92
A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. Expert Opin Biol Ther (2011) 0.92
Promising novel immunotherapies and combinations for prostate cancer. Future Oncol (2009) 0.91
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. Proc Natl Acad Sci U S A (2014) 0.91
IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy. J Biomed Biotechnol (2010) 0.90
Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. Cancer Immunol Immunother (2013) 0.90
Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Am J Ther (2003) 0.90
Poxviral vectors for cancer immunotherapy. Expert Opin Biol Ther (2012) 0.88
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy. Cancer Immunol Immunother (2009) 0.88
Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clin Lung Cancer (2010) 0.88
PSA-based vaccines for the treatment of prostate cancer. Expert Rev Vaccines (2006) 0.88
The role of soluble CD40L in immunosuppression. Oncoimmunology (2013) 0.88
TRICOM vector based cancer vaccines. Curr Pharm Des (2006) 0.87
Angiogenesis inhibition in prostate cancer: current uses and future promises. J Oncol (2010) 0.87
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. J Urol (2010) 0.86
Therapeutic vaccines for prostate cancer. Oncologist (2006) 0.86
Vaccines as monotherapy and in combination therapy for prostate cancer. Clin Transl Sci (2010) 0.85
Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. J Immunol (2014) 0.85
The use of bisphosphonates in cancer patients. Acta Oncol (2007) 0.85
Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer. Clin Genitourin Cancer (2007) 0.85
Hepcidin, anaemia, and prostate cancer. BJU Int (2011) 0.85
Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J (2013) 0.84
Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4). Int J Cancer (2007) 0.84
Immunotherapy in prostate cancer: emerging strategies against a formidable foe. Vaccine (2011) 0.84
Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. Int J Cancer (2013) 0.84
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst (2012) 0.83
A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. Clin Prostate Cancer (2004) 0.83
Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. J Natl Compr Canc Netw (2012) 0.83
The current and emerging role of immunotherapy in prostate cancer. Clin Genitourin Cancer (2010) 0.83